Terms: = Endocrine gland cancer AND PRF1, P14222, PFP, P1, MGC65093, HPLH2, FLH2, ENSG00000180644, 5551 AND Treatment
61 results:
1. [Killing effect of anti-MSLN-iCAR-NK cells derived from induced pluripotent stem cells on ovarian epithelial cancer cells].
Fan RJ; Zhang YF; Wang YY; Wang Y; Zheng W
Zhonghua Fu Chan Ke Za Zhi; 2023 Dec; 58(12):922-929. PubMed ID: 38123198
[No Abstract] [Full Text] [Related]
2. RAD51D Secondary Mutation-Mediated Resistance to PARP-Inhibitor-Based Therapy in HGSOC.
Xu J; Dai Y; Gao Y; Chai R; Lu C; Yu B; Kang Y; Xu C
Int J Mol Sci; 2023 Sep; 24(19):. PubMed ID: 37833926
[TBL] [Abstract] [Full Text] [Related]
3. Glutathione Transferase P1: Potential Therapeutic Target in Ovarian cancer.
Simic P; Pljesa I; Nejkovic L; Jerotic D; Coric V; Stulic J; Kokosar N; Popov D; Savic-Radojevic A; Pazin V; Pljesa-Ercegovac M
Medicina (Kaunas); 2022 Nov; 58(11):. PubMed ID: 36422199
[TBL] [Abstract] [Full Text] [Related]
4. A prospective phase II study of biweekly S-1, leucovorin, and gemcitabine in elderly patients with locally advanced or metastatic pancreatic adenocarcinoma - The Taiwan Cooperative Oncology Group T1217 study.
Bai LY; Li CP; Shan YS; Chuang SC; Chen JS; Chiang NJ; Chen YY; Tsou HH; Chuang MH; Chiu CF; Liu TW; Chen LT
Eur J Cancer; 2022 Sep; 173():123-132. PubMed ID: 35932625
[TBL] [Abstract] [Full Text] [Related]
5. Wilms Tumor 1-Associated Protein Expression Is Linked to a T-Cell-Inflamed Phenotype in Pancreatic cancer.
Xu JL
Dig Dis Sci; 2023 Mar; 68(3):831-840. PubMed ID: 35859262
[TBL] [Abstract] [Full Text] [Related]
6. Retrospective Analysis of the Development of Human Thyroglobulin during Pregnancy in Patients with Treated Non-Recurrent Differentiated Thyroid cancer.
Baumgarten J; Happel C; Groener D; Staudt J; Bockisch B; Sabet A; Grünwald F; Rink T
Curr Oncol; 2022 May; 29(6):4012-4019. PubMed ID: 35735429
[TBL] [Abstract] [Full Text] [Related]
7. Ramucirumab in combination with dacarbazine in patients with progressive well-differentiated metastatic pancreatic neuroendocrine tumors (RamuNET): study protocol for a multicenter single-arm trial.
Krug S; Kegel T; Gress TM; Rinke A; Apostolidis L; Jann H; König A; Hörsch D; Schrader J; Ettrich TJ; Richter M; Steighardt J; Michl P
BMC Cancer; 2021 Nov; 21(1):1206. PubMed ID: 34772353
[TBL] [Abstract] [Full Text] [Related]
8. Meta-analysis identifying epithelial-derived transcriptomes predicts poor clinical outcome and immune infiltrations in ovarian cancer.
Li DF; Tulahong A; Uddin MN; Zhao H; Zhang H
Math Biosci Eng; 2021 Jul; 18(5):6527-6551. PubMed ID: 34517544
[TBL] [Abstract] [Full Text] [Related]
9. Risk of venous thromboembolism in ovarian cancer patients receiving neoadjuvant chemotherapy.
Basaran D; Boerner T; Suhner J; Sassine D; Liu Y; Grisham RN; Tew WP; Gardner GJ; Zivanovic O; Sonoda Y; Long Roche K; Chi DS; Abu-Rustum NR; Soff GA; Jewell EL
Gynecol Oncol; 2021 Oct; 163(1):36-40. PubMed ID: 34312001
[TBL] [Abstract] [Full Text] [Related]
10. NIR Laser Responsive Nanoparticles for Ovarian cancer Targeted Combination Therapy with Dual-Modal Imaging Guidance.
Zhao J; Zhang L; Qi Y; Liao K; Wang Z; Wen M; Zhou D
Int J Nanomedicine; 2021; 16():4351-4369. PubMed ID: 34234430
[TBL] [Abstract] [Full Text] [Related]
11. Oncolytic Adenovirus Coding for a Variant Interleukin 2 (vIL-2) Cytokine Re-Programs the Tumor Microenvironment and Confers Enhanced Tumor Control.
Quixabeira DCA; Zafar S; Santos JM; Cervera-Carrascon V; Havunen R; Kudling TV; Basnet S; Anttila M; Kanerva A; Hemminki A
Front Immunol; 2021; 12():674400. PubMed ID: 34084172
[TBL] [Abstract] [Full Text] [Related]
12. REZOLVE (ANZGOG-1101): A phase 2 trial of intraperitoneal bevacizumab to treat symptomatic ascites in patients with chemotherapy-resistant, epithelial ovarian cancer.
Sjoquist KM; Espinoza D; Mileshkin L; Ananda S; Shannon C; Yip S; Goh J; Bowtell D; Harrison M; Friedlander ML
Gynecol Oncol; 2021 May; 161(2):374-381. PubMed ID: 33637349
[TBL] [Abstract] [Full Text] [Related]
13. Hypofractionated sequential radiotherapy boost: a promising strategy in inoperable locally advanced pancreatic cancer patients.
Mattiucci GC; Boldrini L; Nardangeli A; D'Aviero A; Buwenge M; Cellini F; Deodato F; Dinapoli N; Frascino V; Macchia G; Morganti AG; Valentini V
J Cancer Res Clin Oncol; 2021 Mar; 147(3):661-667. PubMed ID: 33001271
[TBL] [Abstract] [Full Text] [Related]
14. Circulating exosomal circFoxp1 confers cisplatin resistance in epithelial ovarian cancer cells.
Luo Y; Gui R
J Gynecol Oncol; 2020 Sep; 31(5):e75. PubMed ID: 32808501
[TBL] [Abstract] [Full Text] [Related]
15. Targeting G6PD reverses paclitaxel resistance in ovarian cancer by suppressing GSTP1.
Feng Q; Li X; Sun W; Sun M; Li Z; Sheng H; Xie F; Zhang S; Shan C
Biochem Pharmacol; 2020 Aug; 178():114092. PubMed ID: 32535103
[TBL] [Abstract] [Full Text] [Related]
16. The Destruction Of Laser-Induced Phase-Transition Nanoparticles Triggered By Low-Intensity Ultrasound: An Innovative Modality To Enhance The Immunological treatment Of Ovarian cancer Cells.
Xie W; Zhu S; Yang B; Chen C; Chen S; Liu Y; Nie X; Hao L; Wang Z; Sun J; Chang S
Int J Nanomedicine; 2019; 14():9377-9393. PubMed ID: 31819438
[TBL] [Abstract] [Full Text] [Related]
17. Multicentre observational cohort study of implementation and outcomes of laparoscopic distal pancreatectomy.
Lof S; Moekotte AL; Al-Sarireh B; Ammori B; Aroori S; Durkin D; Fusai GK; French JJ; Gomez D; Marangoni G; Marudanayagam R; Soonawalla Z; Sutcliffe R; White SA; Abu Hilal M;
Br J Surg; 2019 Nov; 106(12):1657-1665. PubMed ID: 31454072
[TBL] [Abstract] [Full Text] [Related]
18. FOXP1-induced lncRNA CLRN1-AS1 acts as a tumor suppressor in pituitary prolactinoma by repressing the autophagy via inactivating Wnt/β-catenin signaling pathway.
Wang C; Tan C; Wen Y; Zhang D; Li G; Chang L; Su J; Wang X
Cell Death Dis; 2019 Jun; 10(7):499. PubMed ID: 31235696
[TBL] [Abstract] [Full Text] [Related]
19. A multifunctional-targeted nanoagent for dual-mode image-guided therapeutic effects on ovarian cancer cells.
Chen C; Sun J; Chen S; Liu Y; Zhu S; Wang Z; Chang S
Int J Nanomedicine; 2019; 14():753-769. PubMed ID: 30718954
[TBL] [Abstract] [Full Text] [Related]
20. A Phase II Randomized Trial of Panitumumab, Erlotinib, and Gemcitabine Versus Erlotinib and Gemcitabine in Patients with Untreated, Metastatic Pancreatic Adenocarcinoma: North Central cancer treatment Group Trial N064B (Alliance).
Halfdanarson TR; Foster NR; Kim GP; Meyers JP; Smyrk TC; McCullough AE; Ames MM; Jaffe JP; Alberts SR
Oncologist; 2019 May; 24(5):589-e160. PubMed ID: 30679315
[TBL] [Abstract] [Full Text] [Related]
[Next]
